Ultramarathons and Impact of Phased Electromagnetic Field Therapy (PEMF)

April 1, 2022 updated by: Bruce Johnson, Mayo Clinic

The Pulmonary Consequences of Participating in the UTMB and Hong Kong 100 Ultramarathons and Impact of Phased Electromagnetic Field Therapy (PEMF)

This research is being done to better understand the pulmonary consequences of completing an ultra marathon at altitude and a sea level city.

Study Overview

Detailed Description

Subjects will be asked to undertake three (3) sets of assessments at prescribed time intervals: Baseline (at 72-24h prior to each event), immediately post (within 2h of race completion) and during recovery (within 24-48h of race completion). Each assessment will consist of 1)lung function tests; 2) a saliva and blood sample; 3) a lung and cardiac ultrasound. Subjects will be recruited from a range of age groups and fitness levels, before being divided into a sham or therapy group. Groups will use Pulsed Electromagnetic Field (PEMF) therapy or related sham before the event and during recovery.

Study Type

Interventional

Enrollment (Actual)

72

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Mayo Clinic in Rochester

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

Healthy endurance trained individuals participating in the Ultra Trail du Mont Blanc (UTMB) and/or Hong Kong 100 ultramarathons

Exclusion Criteria:

> 65 years age

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: NON_RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: TRIPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: HK100 Pulsed Electromagnetic Field
20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Hong Kong 100 races. In addition, these athletes will use the pulsed electromagnetic field (PEMF) for the two weeks prior to the race.
PEMF Therapy based on Biological Electromagnetic (BEM) microbial wave technology provides micro-magnetic emissions to the center of the palm (Laogong acupoint). While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
Other Names:
  • Bioboosti
SHAM_COMPARATOR: HK100 Pulsed Electromagnetic Field Sham
20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Hong Kong 100 races. In addition, these athletes will use a PEMF device that doesn't produce electromagnetic fields (sham) for the two weeks prior to the race.
PEMF therapy will be administered however it will not produce micro-magnetic emissions. The therapy will be used on the center of the palm (Laogong acupoint) of each hand. While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
Other Names:
  • Bioboosti Sham
EXPERIMENTAL: UTMB Pulsed Electromagnetic Field
20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Ultra Trail du Mont Blanc (UTMB) races. In addition, these athletes will use the pulsed electromagnetic field (PEMF) for the two weeks prior to the race.
PEMF Therapy based on Biological Electromagnetic (BEM) microbial wave technology provides micro-magnetic emissions to the center of the palm (Laogong acupoint). While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
Other Names:
  • Bioboosti
SHAM_COMPARATOR: UTMB Pulsed Electromagnetic Field Sham
20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Ultra Trail du Mont Blanc (UTMB) races. In addition, these athletes will use a PEMF device that doesn't produce electromagnetic fields (sham) for the two weeks prior to the race.
PEMF therapy will be administered however it will not produce micro-magnetic emissions. The therapy will be used on the center of the palm (Laogong acupoint) of each hand. While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
Other Names:
  • Bioboosti Sham

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in right ventricle end diastolic area (EDA)
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
Cardiac ultrasound (Philips CX50) will be performed to determine left and right ventricular morphology and function. Ultrasound will be performed in accordance with the recommendations of the American Society of Echocardiography guidelines (ASE). Imaging of the ventricles and the diameter during relaxation (diastole) will be captured and evaluated. Normal value for right ventricle EDA indexed to body surface area ranges between 5-12.6 cm^2/m^2 for males and 4.5-11.5 cm^2/m^2 for females .
baseline, within 2 hours of race completion, 24-48 hours post race
Change in tricuspid annular plane systolic excursion (TAPSE)
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
Another ultrasound metric that will be evaluated is tricuspid annular plane systolic excursion (TAPSE) which is used a parameter of global RV function which describes apex-to-base shortening. Normal value for TAPSE is above 16 mm.
baseline, within 2 hours of race completion, 24-48 hours post race
Change in ratio between early mitral inflow velocity and mitral annular early diastolic velocity (E/e')
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
Another ultrasound metric that will be evaluated is early mitral inflow velocity and mitral annular early diastolic velocity (E/e') which is used to evaluate the diastolic or relaxation function of the left ventricle. Normal value for E/e' is <6.
baseline, within 2 hours of race completion, 24-48 hours post race
Change in the ratio of peak velocity flow in early diastole (the E wave) to peak velocity flow in late diastole caused by atrial contraction (the A wave)
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
Another ultrasound metric that will be evaluated is he ratio of peak velocity flow in early diastole (the E wave) to peak velocity flow in late diastole caused by atrial contraction (the A wave) (E/A) which is used to evaluate the diastolic filling of the left ventricle. Normal value for E/A is between 0.8 and 2.
baseline, within 2 hours of race completion, 24-48 hours post race
Change in lung fluid assessed through ultrasound incidence of comet tails
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
Ultrasound will be used to image 28 "windows" covering the 2nd through the 5th intercostal/rib space on the right and left sides of the chest. The number of comet tails observed over these 28 locations will be documented and the change in this number over the course of the study will be evaluated.
baseline, within 2 hours of race completion, 24-48 hours post race
Change in lung fluid assessed through diffusion capacity of the lungs for carbon monoxide and nitric oxide
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
Subjects will take a maximal breath of a test gas mixture, hold that inhalation for 4 seconds and then exhale and the exhaled gas will be analyze to determine the change in gas concentrations between what was inhaled and exhaled. Comparison will be made between the change over time in this ability of gas to move from the lungs to the blood stream.
baseline, within 2 hours of race completion, 24-48 hours post race

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in exhaled nitric oxide
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
The amount of nitric oxide in ones exhaled air will be measured by a handheld device. Levels under 25 parts per billion are normal, more than 35 parts per billion would be a sign of airway inflammation.
baseline, within 2 hours of race completion, 24-48 hours post race
Change in hemoglobin
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
A blood sample will be taken and analyzed to determine the amount of red blood cells and and hemoglobin in the blood. For males normal range for hemoglobin is 13.5-17.5 grams per deciliter and for females normal range for hemoglobin is 12.0-15.5 grams per deciliter. Low values means anemia is present and higher levels is a normal response to altitude.
baseline, within 2 hours of race completion, 24-48 hours post race
Change in hematocrit
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
A blood sample will be taken and analyzed to determine the amount of red blood cells and and hemoglobin in the blood. For males normal range for hematocrit is 38.8-50% and for females normal range for hematocrit is 34.9-44.5% Low values means anemia is present and higher levels is a normal response to altitude.
baseline, within 2 hours of race completion, 24-48 hours post race
Change in cardiac troponin I
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
To determine if signs of cardiac damage, as its presence in the blood is a potential sign of damage to the heart muscle
baseline, within 2 hours of race completion, 24-48 hours post race
Change in B-type natriuretic peptide
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
To determine if signs of cardiac damage, as its presence in the blood is a potential sign of damage to the heart muscle
baseline, within 2 hours of race completion, 24-48 hours post race
Change in cortisol
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
Saliva levels of cortisol will be measured as a metric of stress. Cortisol levels increase when you body is under stress.
baseline, within 2 hours of race completion, 24-48 hours post race

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

December 12, 2016

Primary Completion (ACTUAL)

June 15, 2021

Study Completion (ACTUAL)

June 15, 2021

Study Registration Dates

First Submitted

October 27, 2017

First Submitted That Met QC Criteria

November 2, 2017

First Posted (ACTUAL)

November 6, 2017

Study Record Updates

Last Update Posted (ACTUAL)

April 11, 2022

Last Update Submitted That Met QC Criteria

April 1, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Pulsed Electromagnetic Field therapy (PEMF)

Subscribe